출생 전 및 신생아 유전자 검사 시장 보고서 : 제품 유형, 스크리닝, 질환, 최종 사용자, 지역별(2026-2034년)

The global prenatal and newborn genetic testing market size reached USD 7.5 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 18.3 Billion by 2034, exhibiting a growth rate (CAGR) of 10.17% during 2026-2034. The market share is experiencing steady growth driven by the growing demand for advanced diagnostic and screening devices, the thriving medical industry, and the rising prevalence of congenital malformations and genetic abnormalities in newborn babies.

Prenatal and Newborn Genetic Testing Market Analysis:

• Major Market Drivers: The increasing demand for prenatal and newborn genetic testing and a growing medical industry are driving the prenatal and newborn genetic testing market growth.
• Key Market Trends: Key trends include increasing adoption of genetic testing for personalized medicine in prenatal and newborn care. This is positively impacting the prenatal and newborn genetic testing market trends.
• Geographical Trends: North America leads the prenatal and newborn genetic testing market demand due to the growing number of pregnant women undergoing genetic screening. The prenatal and newborn genetic testing market forecast for Asia Pacific is also expected to witness growth.
• Competitive Landscape: Abbott Laboratories and BGI Group are some of the prenatal and newborn genetic testing market companies driving the prenatal and newborn genetic testing market revenue.
• Challenges and Opportunities: Challenges include ethical and legal considerations. The prenatal and newborn genetic testing market recent opportunities lie in the integration of AI and ML technologies.

Prenatal and Newborn Genetic Testing Market Trends:

High Prevalence of Genetic Diseases in Infants

The fetuses in the womb are affected by several genetic disorders. The inheritance pattern of these genetic illnesses has a role in determining both the chance of recurrence and the risk they pose during pregnancy. Babies that have a parent with a chromosomal anomaly, a family history of genetic disorders, or another kid who has a genetic disease are more likely to have genetic diseases. Infants are significantly more likely to be affected by hereditary disorders. Furthermore, these illnesses are to blame for infant mortality worldwide. For example, the World Health Organization predicted that 7.9 million babies worldwide are born with genetic abnormalities. Therefore, the high prevalence of genetic diseases in infants is driving the prenatal and newborn genetic testing market outlook.

Technological advancements

The growth of the prenatal and newborn genetic testing market report is mostly due to advancements in technology. A number of significant advancements, such as non-invasive prenatal testing and next-generation sequencing, have improved the quality of the screening procedure while maintaining safety requirements that guarantee accuracy and improved outcomes. Furthermore, it is highly recommended that the healthcare industry use these innovations to detect and identify a larger range of genetic abnormalities. It also makes sure that the expectant parents decide what's best for the health and safety of their unborn child. Furthermore, a significant improvement has been made, which raises the transformations' authenticity and dependability.

Increasing awareness and demand

The prenatal and newborn genetic testing market overview has experienced an incredible expansion due to the growing awareness and demand for prenatal and newborn genetic testing. These days, the value of early genetic screening is being recognized by more people, including expectant parents and healthcare professionals. The market's need for innovation has increased as a result of this. By using this innovation, a person can learn about genetic abnormalities that are still present and take timely preventative action to reduce the risk to the lives of the babies. With regard to the health and safety of their unborn child, pregnant parents are capable of making the best decisions. Researchers and investors from all over the world have been drawn to the testing services due to their increasing demand.

Prenatal and Newborn Genetic Testing Industry Segmentation:

Breakup by Product Type:

• Consumables
• Instruments

Consumables account for the majority of the market share

Consumables like testing kits and reagents are fueling the prenatal and newborn genetic testing market recent developments. These kits are really important for checking if babies have any genetic problems before they're born or right after they're born. Also, new technology is making these tests better and easier to do. As more people want these tests, the market for the supplies needed for them is growing, too. Doctors need these supplies to offer good genetic testing services. So, these supplies are a big part of why prenatal and newborn genetic testing is becoming more popular and helpful for families.

Breakup by Screening:

• Non-invasive Prenatal Testing
• Chorionic Villus Sampling
• Amniocentesis
• Maternal Serum Screening

Non-invasive prenatal testing holds the largest share of the industry

NIPT is the best way to check babies before they're born. It doesn't require taking samples from the womb. It depends on simple blood tests from the mother. This method is safer and more comfortable. It offers accurate results in detecting genetic conditions like Down syndrome. It doesn't involve any complications associated with invasive techniques. Due to these benefits, more expecting parents are opting for NIPT. It's the top choice for prenatal testing as it's convenient, safe, and gives reliable results.

Breakup by Disease:

• Downs Syndrome
• Phenylketonuria
• Cystic Fibrosis
• Sickle Cell Anemia

Downs syndrome represents the leading market segment

The largest prenatal and newborn genetic testing market recent price is held by Down syndrome testing. An additional copy of chromosome 21 causes this disorder. It is essential for aspiring parents to get tested for Down syndrome in order to plan for any particular care their child may require. The accuracy and accessibility of Down syndrome diagnostics have increased due to technological breakthroughs. Pregnant women are choosing these tests more frequently in order to protect the health of their unborn child. Furthermore, these examinations are advised by medical professionals as standard prenatal care. There is a large demand for testing, which has led to its dominance in the genetic testing market.

Breakup by End User:

• Hospital
• Maternity and Specialty Clinics
• Diagnostic Centers

Hospital represents the leading market segment

Hospitals are at the top of the market. They are essential in the provision of many medical services, such as genetic testing. Patients seeking genetic testing services prefer hospitals as they are dependable and convenient. Hospitals provide accurate testing and appropriate counselling for patients and their families since they have highly qualified staff and modern facilities. Hospitals also frequently work with medical specialists to provide proper care. People are drawn to hospitals due to their reputation for providing high-quality healthcare services. They thereby lead the market share, confirming their status as the main suppliers of genetic testing services.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America leads the market, accounting for the largest prenatal and newborn genetic testing market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

With a sizable portion of the global market for prenatal and newborn genetic testing, North America currently has a prominent position. The prenatal and newborn genetic testing market has strengthened its position in the region due to a significant number of companies operating in the diagnostics and screening sectors, in addition to the region's increased prevalence of genetic abnormalities and a huge pool of highly aware parents. Also, an increasing number of expecting mothers in this area are having their genetics screened, which supports the market's expansion. The strong purchasing power and growing public knowledge are anticipated to fuel market expansion. For example, March 21st is designated as World Down Syndrome Day each year to raise awareness of the diagnosis and care of individuals with Down syndrome.

Leading Key Players in the Prenatal and Newborn Genetic Testing Industry:

The market for prenatal and newborn genetic testing is expanding rapidly due to the major companies' creativity, innovation, teamwork, and cutting-edge technology. Some of the biggest businesses are constantly working to improve the testing process's quality and safety. The key players are primarily concerned with growing the test panels' capacity to screen for and identify genetic diseases. Additionally, the market for prenatal and newborn genetic testing is expanding at an even faster rate with the help of technological advancements. Furthermore, accessibility and flexibility are guaranteed through partnerships with regulatory bodies and the healthcare industry. Both the expecting parents and their newborns greatly benefit from prenatal and newborn genetic testing.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• Abbott Laboratories
• BGI Group
• Bio-Rad Laboratories Inc.
• F. Hoffmann-La Roche AG
• Illumina Inc.
• Laboratory Corporation of America Holdings
• Natera Inc.
• PerkinElmer Inc.
• Quest Diagnostics Incorporated
• Ravgen Inc.

Key Questions Answered in This Report:

• How has the global prenatal and newborn genetic testing market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global prenatal and newborn genetic testing market?
• What is the impact of each driver, restraint, and opportunity on the global prenatal and newborn genetic testing market?
• What are the key regional markets?
• Which countries represent the most attractive prenatal and newborn genetic testing market?
• What is the breakup of the market based on the product type?
• Which is the most attractive product type in the prenatal and newborn genetic testing market?
• What is the breakup of the market based on the screening?
• Which is the most attractive screening in the prenatal and newborn genetic testing market?
• What is the breakup of the market based on the disease?
• Which is the most attractive disease in the prenatal and newborn genetic testing market?
• What is the breakup of the market based on the end user?
• Which is the most attractive end user in the prenatal and newborn genetic testing market?
• What is the competitive structure of the market?
• Who are the key players/companies in the global prenatal and newborn genetic testing market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Prenatal and Newborn Genetic Testing Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product Type

• 6.1 Consumables
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Instruments
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Screening

• 7.1 Non-invasive Prenatal Testing
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Chorionic Villus Sampling
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Amniocentesis
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Maternal Serum Screening
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Disease

• 8.1 Downs Syndrome
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Phenylketonuria
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Cystic Fibrosis
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Sickle Cell Anemia
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by End User

• 9.1 Hospital
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Maternity and Specialty Clinics
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Diagnostic Centers
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 Drivers, Restraints, and Opportunities

• 11.1 Overview
• 11.2 Drivers
• 11.3 Restraints
• 11.4 Opportunities

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Abbott Laboratories
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
  • 15.3.2 BGI Group
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
  • 15.3.3 Bio-Rad Laboratories Inc.
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
  • 15.3.4 F. Hoffmann-La Roche AG
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
  • 15.3.5 Illumina Inc.
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
  • 15.3.6 Laboratory Corporation of America Holdings
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
  • 15.3.7 Natera Inc.
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
  • 15.3.8 PerkinElmer Inc.
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
  • 15.3.9 Quest Diagnostics Incorporated
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
  • 15.3.10 Ravgen Inc.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio